Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
In the run-up to the next reimbursement reform in April 2022, the Ministry of Health, Labor and Welfare (MHLW) will be discussing ways to ensure the transparency and predictability of the drug pricing system, new health minister Shigeyuki Goto said…
To read the full story
Related Article
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
REGULATORY
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…